EKSO BIONICS (EKSO) AI Stock Analysis

• Market Cap: $8.59M
• Dividend Yield: N/A
• Average Volume (3M): 250.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: -19.32%
• EPS Growth: 44.73%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -1.24
• Shares Outstanding: 2,611,788
• 10 Day Avg. Volume: 218,426
• 30 Day Avg. Volume: 250,523
• PEG Ratio: <0.01
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.93
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 0.28
• Enterprise Value/Gross Profit: 6.90
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $34.75
• Price Target Upside: 857.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $3.50 ▼(-3.58%Downside)

EKSO BIONICS faces significant financial challenges with negative profitability and reliance on external financing being the most impactful concerns. The technical analysis supports a bearish outlook, compounded by valuation difficulties due to negative earnings. However, strategic initiatives and potential recovery in sales offer some optimism, slightly uplifting the overall score.

Positive Factors

Distribution Network Expansion

Ekso continues to expand its distribution network for the Ekso Indego Personal product.

Revenue Growth Outlook

Revenue growth is expected in both the legacy enterprise business and Indego Personal, indicating a positive outlook for 2025.

Strategic Partnerships

Strategic partnerships have been formed to broaden access to Ekso Indego Personal and navigate the reimbursement process, potentially expanding the market and driving long-term value for Ekso.

Negative Factors

Enterprise Revenue Decline

Softer enterprise revenue due to customer budget cuts.

Medicare Reimbursement Complexity

Numerous activities must take place before a Medicare enrollee receives a unit, complicating the reimbursement process.

Revenue Decline

Ekso Bionics reported a 2% year-over-year decline in total revenue for 2024, mainly due to lower enterprise sales.

EKSO BIONICS Business Overview & Revenue Model

Company Description

Ekso Bionics (EKSO) is a pioneering company in the field of wearable robotics and exoskeleton technology. Founded in 2005 and headquartered in Richmond, California, Ekso Bionics develops and manufactures powered exoskeletons that enhance human strength, endurance, and mobility. The company's core products are designed for medical and industrial applications, helping individuals with lower extremity weakness or paralysis to stand and walk, as well as aiding workers in performing physically demanding tasks more safely and efficiently.

How the Company Makes Money

Ekso Bionics generates revenue through the sale and leasing of its exoskeleton products, primarily targeting the healthcare and industrial sectors. In healthcare, Ekso Bionics markets its exoskeletons to rehabilitation centers and hospitals, where they are used as therapeutic tools to aid in the recovery of patients with spinal cord injuries, strokes, and neurological conditions. The company also offers training and support services to ensure effective product use, contributing to its revenue streams. In the industrial sector, Ekso Bionics sells or leases its exoskeletons to companies looking to improve worker safety and productivity by reducing physical strain and the risk of injuries. Additionally, the company may engage in partnerships or collaborations with research institutions and organizations to further develop and expand its technology, potentially creating additional revenue opportunities.

EKSO BIONICS Financial Statement Overview

Summary

EKSO BIONICS faces ongoing financial challenges with negative profitability and cash flow metrics. Despite slight improvements in operational efficiency, the company struggles with persistent losses and relies on external financing. The stable equity position and moderate leverage offer some stability, but consistent revenue growth and profitability are crucial for long-term sustainability.

Income Statement

EKSO BIONICS has shown a volatile revenue trajectory with a slight revenue decline of 1.94% from 2023 to 2024. The gross profit margin improved to 53.06% in 2024 from 49.68% in 2023, indicating efficiency in controlling direct costs. However, the company continues to face challenges with profitability, as evidenced by a negative net profit margin of -63.21% in 2024, despite improving from -83.17% in 2023. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

EKSO BIONICS' balance sheet reflects a stable equity position with an equity ratio of 47.68% as of 2024. The debt-to-equity ratio stands at 0.47, indicating moderate leverage, which has slightly decreased from 0.57 in 2023. However, the return on equity remains negative at -89.17% due to persistent net losses, highlighting a challenging environment for shareholder returns.

Cash Flow

The cash flow statement reveals a negative free cash flow for 2024, although it improved by 19.46% compared to 2023. The operating cash flow to net income ratio is 0.87, suggesting that operational cash generation is not sufficient to cover net losses. The company is heavily reliant on financing activities to support cash flow needs.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.93M	18.28M	12.91M	11.25M	8.88M
Gross Profit	9.51M	9.08M	6.21M	6.75M	5.07M
EBITDA	-9.45M	-13.20M	-14.04M	-9.09M	-15.07M
Net Income	-11.33M	-15.20M	-14.60M	-8.43M	-16.95M
Balance Sheet
Total Assets	26.65M	28.92M	40.90M	49.17M	20.60M
Cash, Cash Equivalents and Short-Term Investments	6.49M	8.64M	20.52M	40.41M	12.86M
Total Debt	5.98M	7.17M	7.50M	2.22M	3.86M
Total Liabilities	13.95M	16.31M	15.46M	11.95M	16.16M
Stockholders Equity	12.71M	12.61M	25.44M	37.22M	4.43M
Cash Flow
Free Cash Flow	-9.88M	-12.21M	-14.88M	-11.21M	-8.76M
Operating Cash Flow	-9.85M	-12.05M	-14.69M	-11.16M	-8.76M
Investing Cash Flow	-37.00K	-157.00K	-5.17M	-59.00K	0.00
Financing Cash Flow	7.77M	348.00K	176.00K	38.71M	10.70M

EKSO BIONICS Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EKSO, the sentiment is Negative. The current price of 3.63 is below the 20-day moving average (MA) of 3.72, below the 50-day MA of 3.86, and below the 200-day MA of 7.88, indicating a bearish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 46.55 is Neutral, neither overbought nor oversold. The STOCH value of 26.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EKSO.

EKSO BIONICS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.47B	0.53	-62.70%	2.38%	14.92%	0.82%
HBIO	51 Neutral	$23.40M	―	-138.80%	―	-14.41%	-549.88%
EKSO	48 Neutral	$8.59M	―	-96.44%	―	-19.32%	44.73%
MLSS	41 Neutral	$38.23M	―	-88.36%	―	-9.13%	30.04%
FEMY	40 Neutral	$28.14M	―	-239.87%	―	61.97%	-6.89%

EKSO BIONICS Corporate Events

Ekso Bionics Announces Reverse Stock Split Approval

On May 16, 2025, Ekso Bionics’ stockholders approved a reverse stock split at a 1-for-15 ratio, which will take effect on June 2, 2025. The split aims to increase the company’s stock price to meet Nasdaq’s minimum bid requirement, reducing the number of outstanding shares from approximately 35.5 million to 2.4 million.

The most recent analyst rating on (EKSO) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.

Ekso Bionics Approves Reverse Stock Split Plan

On May 16, 2025, Ekso Bionics held its Annual Meeting of Stockholders where several key proposals were approved, including a reverse stock split at a ratio of 1-for-15, effective May 27, 2025. This move is primarily intended to increase the per-share trading price and help the company regain compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

The most recent analyst rating on (EKSO) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.